The pharmaceutical industry continues to undergo a major transformation, primarily driven by the integration of artificial intelligence (AI) in drug research and development (R&D). Sanofi, a leader in the sector, exemplifies this trend by integrating AI at every stage of its value chain, from molecular discovery to data governance. Concurrently, Bristol Myers Squibb (BMS) has recently invested in the Nvidia DGX SuperPOD system to accelerate drug discovery through AI. These technological advancements are accompanied by regulatory and ethical challenges, necessitating a rapid adaptation of legislative frameworks.
Débloquez l'Analyse Complète
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.
